SARS-CoV-2 in-vitro and in-vivo research

Syngene offers SARS-CoV-2 in-vitro and in-vivo research, in partnership with Foundation for Neglected Disease Research (FNDR). This non-exclusive partnership, aims to provide a range of non-BSL3 and BSL3 in vitro and in vivo capabilities to facilitate a wide variety of studies on SARS-CoV-2, and prepare us for the next wave of the corona virus pandemic.

Our joint offerings include:

  • In vitro immune profiling, mechanism of action studies (non-BSL3)
  • In vitro immunological assays (non-BSL3 cell-based assays and cytotoxicity assays)
  • In vitro cell-based assays for screening of novel compounds and libraries for antiviral activity, including pre-and post-entry viral inhibition studies, antiviral synergy studies, and neutralization assays for antibodies and vaccines against wild type SARS-CoV-2 strain
  • In vivo efficacy assay in Golden Syrian hamster with wild type SARS-CoV-2 infection model for antiviral inhibition, vaccines, neutralizing antibodies, and biologicals, for understanding biology, pathology, immunology parameters in an infection.